China-heavy syndicate backs $80M series B for antiviral play Ansun

Ansun’s latest venture raise is in keeping with the San Diego-based antiviral company’s long-term strategy to add Chinese investors to help it penetrate the China market.

Oceanpine Capital led Ansun BioPharma Inc.’s $80 million series B round with participation by fellow existing Chinese investors Yuanming Capital, Lilly Asia Ventures, Matrix Partners China, 3E Bioventures and LYFE Capital. Among the trio of new investors were two more Chinese investors, Great Bay Area Homeland Development Fund and Junson Capital, as well as KIP, according to the round’s financial adviser China Renaissance...